10 Strategic Foundations for Early Drug Development Guide 10 Strategic Foundations for Early Drug Development Discover effective Early Drug Development strategies to navigate early development with confidence and clarity. Download…CertaraNovember 26, 2025
Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges Publication Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges The paper reviews current applications of pediatric PBPK across therapeutic areas and outlines where PBPK…CertaraNovember 21, 2025
Using M&S to Evaluate Oncology Drug Dosing Blog Using M&S to Evaluate Oncology Drug Dosing Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…CertaraNovember 14, 2025
Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix® On-Demand Webinar Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix® Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…CertaraNovember 13, 2025
Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema Publication Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…CertaraNovember 12, 2025
Supporting KalVista’s NDA Submission for a Novel HAE Treatment Case Study Supporting KalVista’s NDA Submission for a Novel HAE Treatment To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…Danielle PillsburyNovember 12, 2025
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Case Study Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…CertaraNovember 10, 2025
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns On-Demand Webinar Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns Improve pediatric drug development with Certara’s Pediatric Practice, MIDD expertise for PIPs/PSPs, dose selection, regulatory…CertaraNovember 10, 2025
Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient On-Demand Webinar Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient Watch the on-demand webinar on avoiding drug launch failure. Learn how smarter development, evidence, and…CertaraNovember 6, 2025
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation Publication Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…CertaraNovember 5, 2025